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Abstract
Therapy-responsive biomarkers are an important and unmet need in themuscular dystrophy ﬁeld where new treatments are
currently in clinical trials. Byusing acomprehensive high-resolutionmass spectrometryapproach andwesternblot validation,we
found that two fragments of themyoﬁbrillar structural proteinmyomesin-3 (MYOM3) are abnormally present in sera ofDuchenne
muscular dystrophy (DMD)patients, limb-girdlemusculardystrophy type2D (LGMD2D) and their respective animalmodels. Levels
of MYOM3 fragmentswere assayed in therapeutic model systems: (1) restoration of dystrophin expression by antisense
oligonucleotide-mediated exon-skipping inmdxmice and (2) stable restoration of α-sarcoglycan expression in KO-SGCAmice by
systemicinjectionofaviralvector.FollowingadministrationofthetherapeuticagentsMYOM3wasrestoredtowardwild-typelevels.
IntheLGMDmodel,wheredifferentdosesofvectorwereused,MYOM3restorationwasdose-dependent.MYOM3fragmentsshowed
lower inter-individual variability comparedwith the commonly used creatine kinase assay, and correlated better with the
restoration of the dystrophin-associated protein complex andmuscle force. These data suggest that the MYOM3 fragments hold
promise for minimally invasive assessment of experimental therapies for DMD and other neuromuscular disorders.
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Introduction
The dystrophin-associated protein complex (DAPC) consists of
several transmembrane and intracellular scaffolding elements
implicated in maintaining the structure and morphology of
vertebrate muscle ﬁbres. Loss-of-function mutations in genes
encoding these proteins give rise to different forms of muscular
dystrophy. The absence of functional dystrophin or sarcogly-
cans in the DAPC is accompanied by a strong destabilization of
the complex at the sarcolemma (1). As a consequence, muscle
ﬁbres become more sensitive to mechanical damage leading to
muscle degeneration, chronic inﬂammation and an increase in
ﬁbrosis—hallmarks of the dystrophic phenotype (2). The most
prevalent and severe disease is Duchenne muscular dystrophy
(DMD), an X-linked disorder caused by mutations in the dys-
trophin gene, with a world-wide incidence of 1/5000 male new-
borns. DMD patients usually lose the ability to walk around the
age of 12 and die in their third or fourth decade due to cardio-
respiratory complications (3). Deﬁciencies in the sarcoglycan
genes are usually less severe but can also be accompanied by
cardiac problems (4,5).
Recently, substantial progress in the development of thera-
peutic approaches for the treatment of muscular dystrophies
has been accomplished. Therapies for DMD based on the deliv-
ery ofminidystrophin (6) or antisense oligonucleotide-mediated
exon-skipping (7–10) are in pre-clinical evaluation or in phase
I–III clinical trials. The small-molecule compound Ataluren
(11,12) has recently obtained conditional marketing authoriza-
tion for the treatment of DMD. Furthermore, a long-term, sus-
tained restoration of α-sarcoglycan (Sgca) and γ-sarcoglycan
(Sgcg) expression was observed following intramuscular gene
transfer to muscles of patients with limb-girdle muscular dys-
trophy types 2D (LGMD2D) (13) and 2C (14) respectively. With
recent progress in pharmaco- or gene-therapy formuscular dys-
trophies there is a growing need for minimally invasive bio-
markers that can be used to assess and monitor the efﬁcacy of
therapy. Indeed, in order to evaluate the efﬁciency of a treat-
ment during animal studies, researchers have unlimited access
to different types of biopsies or necropsies. In contrast, trials in
humans impose ethical restrictions requiring minimally inva-
sivemethods to assess andmonitor the efﬁcacy of therapy. Cur-
rent methods include functional evaluation scales to measure
patients’ status (15–17), measurement of the level of fatty inﬁl-
tration by magnetic resonance imaging (MRI) (18) and quantiﬁ-
cation of serum microRNAs (19–21) or urinary proteins (22).
The biomarker most commonly used for DMD is serum creatine
kinase (CK), which leaks into the blood stream upon muscle
damage.However, CKdemonstrates variations due to physical ac-
tivity, muscle injury, cramping, toxic agents or age (23,24). Thus,
although serum CKmeasurement is a useful diagnostic biomark-
er (25), it is not appropriate to predict the course of disease, sever-
ity of pathology or to monitor the efﬁcacy of treatment.
Variations in the composition of serum proteome are con-
sidered a promising source of biomarkers (26). In the present
study, serum samples from DMD patients and healthy controls
were compared using a comprehensive high-resolution mass
spectrometry approach and several tens of proteinswith altered
levels were revealed by label-free protein quantiﬁcation ana-
lysis. Among these proteins, the myoﬁbrillar structural protein
myomesin-3 (MYOM3), which was more abundant in DMD pa-
tient sera than in healthy controls, was chosen for detailed ana-
lysis. MYOM3 was present in sera as two internal fragments of
100 and 130 kDa rather than as an intact protein. Importantly,
these fragments demonstrated lower inter-individual varia-
tions compared to CK. High levels of these MYOM3 fragments
were also detected in sera from LGMD2D patients, as well as
in animal models of DMD and several limb-girdle muscular
dystrophies.
In the dystrophin-deﬁcientmdxmouse, these fragments were
more reliable for the early detection of the disease and less
sensitive to physical exercise when compared to CK. MYOM3
fragments were also superior when compared to CK for themon-
itoring the restoration of the DAPC and correlated to the rescue of
physical force after gene therapy treatment of LGMD2D mouse
model. Taken together, our data suggest that MYOM3 fragments
are biomarkers for the detection, evaluation and treatment
monitoring of DMD, LGMD2D and potentially for other forms
of muscular dystrophy associated with increased turnover of
sarcomeric proteins.
Results
Detection of serum proteins with altered levels
in DMD patients by mass spectrometry
Serumsamples from39DMDpatients and 38 control subjects col-
lected in USA as part of the AdvancedDiagnostics for New Thera-
peutic Approaches (ADNA) project (http://www.institut-merieux.
com/projetssante_adna.php) were analysed using a mass spec-
trometry approach. To reduce the number of LC-MS/MS ana-
lyses, the samples were organized into four groups (G1: young
DMD from 3 to 10 years old; G2: older DMD from 12 to 20 years
old; G3: young controls from 3 to 10 years old and G4: older con-
trols from 12 to 20 years old) subdivided in a total of 12 pools ac-
cording to the patient’s age (Table 1). Each pool included sera
from at least four individuals where serum of each individual
was equally represented. In order to ensure deep proteome
coverage, the pools were immunodepleted for the 12 major
serum proteins.
Mass spectrometry analysis of serum samples of all 12 sub-
groups enabled the identiﬁcation a total of 3329 unique peptides
matching 378 proteins (with a false discovery rate less than 0.01).
Among those, 69% of protein identiﬁcation calls (260 proteins)
were based on spectra from two or more peptides. To reveal
Table 1. Schema of samples assembling into groups and subgroups.DMDG1-1 to G1-4: serum from young DMDpatients of 3 to 10 years old;DMD
G2-1 to G2-2: serum fromDMD patients of 12 to 20 years old.Healthy controls G3-1 to G3-4 and G4-1 to G4-2: age-matched healthy controls to the
young and older DMD patients respectively. Numbers below each pool indicate the interval of age and the number of patients (in brackets)
DMD G1–1 G1–2 G1–3 G1–4 G2–1 G2–2
Age (number) 3–4 (7) 4–6 (11) 6–7 (4) 7–10 (4) 12–16 (6) 16–20 (7)
Healthy controls G3–1 G3–2 G3–3 G3–4 G4–1 G4–2
Age (number) 3–4 (5) 4–6 (6) 6–7 (5) 7–10 (5) 12–16 (10) 16–20 (7)
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proteins differentially present in sera from DMD and healthy
individuals, the data were analysed by a label-free quantiﬁcation
approach using the following parameters: number of peptides≥2;
Mascot protein score (http://www.matrixscience.com/) ≥50 and
fold change ≥2. The analysis of young DMD patients with their
age-matched controls (G1 versus G3 groups) revealed 24 proteins
more abundant in DMD and 13 in healthy subjects (Table 2). The
top 10 proteins with the lowest P-value were more abundant in
DMD patients and either involved in muscle energy metabolism
(pyruvate kinase PKM, L-lactate dehydrogenase B chain, CK-M,
alanine aminotransferase 1, β-enolase, carbonic anhydrase 3,
fructose-bisphosphate aldolase A), in sarcomere organization
(myomesin-3, myosin-7) or costamere organization (vinculin).
Comparison of older DMD patients with their age-matched
controls (G2 versus G4) using the same parameters resulted in
only nine altered proteins: ﬁve proteins more abundant in DMD
(CK-M, adiponectin, fructose-bisphosphate aldolase A, L-lactate
dehydrogenase B chain and haemoglobin β) and four in healthy
subjects (gelsolin, phosphatidylcholine-sterol acyltransferase,
cadherin-13 and cartilage acidic protein 1) (Table 3). Only four
of these proteins (CK-M, fructose-bisphosphate aldolase A, L-lac-
tate dehydrogenase B chain and haemoglobin β) were differen-
tially abundant in both DMD age groups according to the mass
spectrometry analysis. Importantly, the expression ratios for
these four proteins inDMDversus healthy controlswere substan-
tially lower in older DMDpatients as compared to the youngDMD
group (19.5; 3.3; 2.2 and 2.4 folds in older DMDversus 39.8; 14.2; 5.4
and 3.6 times in young, respectively). The decrease in the number
of proteins with altered levels and in magnitude of their fold
changes is most probably due to the drastic decrease of muscle
mass in older DMD patients and relative immobility of these pa-
tients. Interestingly, label-free analysis of young and older DMD
patients (G1 versus G2) revealed eight secreted proteins that in-
creased in abundancewith patient age (dopamine β-hydroxylase:
3-fold, adiponectin: 3-fold, serum amyloid P-component: 3-fold,
insulin-like growth factor-binding protein complex acid labile
Table 2. List of proteinswith altered levels betweenG1 andG3 groups (youngDMDand age-matchedhealthy controls) classiﬁed by the decrease in
the ratio DMD/healthy (fold change)
No. accession Description Localization Peptides Score ANOVA
(P-value)
Fold
change
MYG_HUMAN Myoglobin Cytoplasm 4 195 2.7e-03 234.8
MYOM2_HUMAN MYOM2 Myoﬁbril 10 390 9.8e-05 100.1
MYOM3_HUMAN MYOM3 Myoﬁbril 11 491 1.5e-05 49.7
TPIS_HUMAN Triosephosphate isomerase Cytoplasm 3 128 2.3e-03 48.4
AATC_HUMAN Aspartate aminotransferase Cytoplasm 3 75 4.7e-04 45.7
KCRM_HUMAN CK-M Cytoplasm 15 849 2.9e-05 39.8
MYH7_HUMAN Myosin-7 Myoﬁbril 11 520 2.2e-05 38.3
ENOB_HUMAN β-enolase Cytoplasm 4 178 7.4e-05 34.8
G6PI_HUMAN Glucose-6-phosphate isomerase Cytoplasm/Secreted 4 130 1.6e-03 29.5
CAH3_HUMAN Carbonic anhydrase 3 Cytoplasm 5 182 8.6e-05 23.9
FLNC_HUMAN Filamin-C Myoﬁbril 4 145 4.3e-04 19.4
ALAT1_HUMAN Alanine aminotransferase 1 Cytoplasm 4 127 3.0e-05 15.6
ALDOA_HUMAN Fructose-bisphosphate aldolase A Cytoplasm 15 729 9.3e-05 14.2
KPYM_HUMAN Pyruvate kinase PKM Cytoplasm 16 845 1.1e-05 12.8
TITIN_HUMAN Titin Myoﬁbril 14 495 1.9e-03 10.8
VINC_HUMAN Vinculin Cytoplasm/Membrane 2 74 7.2e-05 10.3
PYGM_HUMAN Glycogen phosphorylase, muscle form Cytoplasm 8 257 6.1e-04 9.9
LDHA_HUMAN L-lactate dehydrogenase A chain Cytoplasm 8 378 9.1e-04 9.5
HPT_HUMAN Haptoglobin Secreted 29 1867 1.5e-04 7.6
HBD_HUMAN Haemoglobin subunit δ Cytoplasm 3 100 5.1e-03 6.2
LDHB_HUMAN L-lactate dehydrogenase B Cytoplasm 10 598 2.4e-05 5.4
HBB_HUMAN Haemoglobin subunit β Cytoplasm 7 552 8.0e-03 3.6
HBA_HUMAN Haemoglobin subunit α Cytoplasm 7 407 5.3e-03 3.4
TPM2_HUMAN Tropomyosin βchain Myoﬁbril 5 170 2.0e-02 2.6
VASN_HUMAN Vasorin Membrane 4 135 4.0e-02 0.5
ALS_HUMAN Insulin-like growth factor-binding protein complex Secreted 22 1096 1.0e-02 0.5
PHLD_HUMAN Phosphatidylinositol-glycan-speciﬁc phospholipase D Secreted 9 533 4.7e-03 0.5
CHL1_HUMAN Neural cell adhesion molecule L1-like protein Membrane/Secreted 2 66 3.0e-02 0.5
COL11_HUMAN Collectin-11 Secreted 2 72 2.6e-03 0.4
CADH5_HUMAN Cadherin-5 Membrane 6 220 2.0e-03 0.4
CD109_HUMAN CD109 antigen Membrane 2 59 3.0e-02 0.4
LBP_HUMAN Lipopolysaccharide-binding protein Secreted 7 386 5.0e-03 0.4
CRAC1_HUMAN Cartilage acidic protein 1 Secreted 6 223 2.0e-02 0.4
C4BPB_HUMAN C4b-binding protein Secreted 4 207 2.0e-02 0.4
CNDP1_HUMAN β-Ala-His dipeptidase Secreted 8 294 4.2e-03 0.3
DPP4_HUMAN Dipeptidyl peptidase 4 Membrane/Secreted 5 162 5.5e-03 0.3
CETP_HUMAN Cholesteryl ester transfer protein Secreted 7 296 8.2e-04 0.2
Top 10 proteins with the lowest P-value are in bold. All shown proteins passed thresholds of peptide numbers ≥2, a score≥50, a fold change ≥ 2 and a P-value ≤ 0.05.
Peptides: number of peptides identiﬁed for a given protein. Score: Mascot protein score.
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subunit: 3-fold, β-Ala-His dipeptidase: 5-fold, insulin-like growth
factor I: 5-fold).
Levels of MYOM3 demonstrate less inter-individual
variations compared to CK in DMD patients
Elevated levels of cytosolic proteins such as CK in the blood are
now widely used as the ﬁrst stage of DMD diagnosis (24,27).
Therefore, it was appealing to compare serum levels of CK with
one of the myoﬁbrillar structural proteins found in the present
study. Serum biomarkers are often presented by truncated frag-
ment of the full-length proteins, thus making difﬁcult ﬁnding
of commercial antibodies for the speciﬁc fragment (28). In our
hands, of the eleven antibodies tested against the three myoﬁ-
brillar structural proteins (MYOM2, MYOM3 and Myosin 7) with
the highest high fold change and lowest P-value between DMD
and healthy controls (Table 2) only antibody against MYOM3
was efﬁcient in immunoblot analysis. MYOM3 (UniProtKB #
Q5VTT5), a protein of 1437 amino acids (162.2 kDa), is a member
of a family of closely related structural proteins detected at the
M-band of the sarcomere in striated skeletal muscles: MYOM1,
MYOM2 (or M protein) and MYOM3. These proteins are involved
in sarcomere stability and resistance during intense or sustained
stretching (29).
Western blot analysis of serum from DMD patients with an
anti-MYOM3 antibody targeting amino acids 887–1178 of the
protein revealed the presence of two bands of 100 and 130 kDa
respectively (Fig. 1). To identify the position of these fragments
within the protein, they were puriﬁed by immunoprecipitation,
separated by SDS-PAGE and analysed by mass spectrometry
separately (Table 4). The obtained peptide coverages of the frag-
ments (total 55 peptides covering amino acid 254–1331 for the
upper fragment and 38 peptides covering the sequence from
amino acid 476–1331 for the lower fragment) suggest that
both fragments have similar C-terminal end but different
N-terminus. Minimum molecular weight of the fragments
based on the positions of the most N-terminal and C-terminal
identiﬁed peptides is equal to 121 kDa for the upper fragment
(1077 aa) and 96 kDa (855 aa) for the lower fragment, which ﬁt
well with the size of the fragments estimated by SDS-PAGE
(130 and 100 kDa respectively). Importantly, fragments of the
same size were barely detectable in sera from healthy subjects
by Western blot analysis (Fig. 1), thus validating the mass
spectrometry data.
Wenext compared the levels of theMYOM3 fragments andCK
in all 103 subjects from the US cohort. The serum expression le-
vels of both MYOM3 fragments were determined byWestern blot
analysis and CK assessed by measuring its enzymatic activity
(Fig. 2). In accordance with the mass spectrometry data, results
showed that expression levels of both, CK and the MYOM3 frag-
ments, were much higher in young DMD patients compared to
the respective healthy controls (ratio DMD/Control: MYOM3 = 284
and CK = 193) (Fig. 2A and B). In older DMD patients, the expres-
sion levels of CK and MYOM3 fragments were respectively 14
Table 3. List of proteins with altered levels in serum samples between G2 and G4 groups (older DMD and age-matched healthy controls) classiﬁed
by the decrease in the ratio DMD/healthy (fold change)
No. accession Description Localization peptides Score ANOVA (P-value) Fold change
KCRM_HUMAN CK-M Cytoplasm 3 96 1.0e-02 19.5
ADIPO_HUMAN Adiponectin Secreted 3 213 3.0e-02 4.4
ALDOA_HUMAN Fructose-bisphosphate aldolase A Cytoplasm 2 84 3.0e-02 3.3
HBB_HUMAN Haemoglobin subunit β Cytoplasm 9 632 8.4e-03 2.4
LDHB_HUMAN L-lactate dehydrogenase B chain Cytoplasm 6 223 4.0e-02 2.2
GELS_HUMAN Gelsolin Cytoplasm 32 2287 1.0e-02 0.5
LCAT_HUMAN Phosphatidylcholine-sterol acyltransferase Secreted 6 295 1.0e-02 0.4
CAD13_HUMAN Cadherin-13 Membrane 2 86 5.8e-03 0.4
CRAC1_HUMAN Cartilage acidic protein 1 Secreted 3 105 1.0e-02 0.2
All shown proteins passed thresholds of peptide numbers ≥2, a score≥ 50, a fold change ≥ 2 and a P-value ≤ 0.05. Peptides: number of peptides identiﬁed for a given
protein. Score: Mascot protein score.
Figure 1.Western blot analysis of MYOM3 in pools of sera from subgroups of young (G1) and older (G2) DMD patients as well as young (G3) and older (G4) healthy subjects.
(A) normal exposure; (B) boosted exposure. For explanation of groups and subgroups see Table 1. Fifty micrograms of serum proteins were loaded in each well.
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Table 4. List of MYOM3 peptides identiﬁed by mass spectrometry in upper (∼130 kDa) and lower (∼100 kDa) bands from DMD patient serum
# Position Sequence Ion score
(Upper band)
Ion score
(Lower band)
1 254–263 DAGFDSEIFK 24
2 265–283 STFGPSVEFTSVLKPVFAR 44
3 320–326 KILYTDR 19
4 321–326 ILYTDR 12
5 338–346 EDEGLYMVR 57
6 347–354 VPSPFGPR 44
7 355–363 EQSTYVLVR 48
8 364–380 DAEAENPGAPGSPLNVR 54
9 401–411 GNPITAYTIER 40
10 461–474 ASELVVMGDHDAAR 54
11 476–486 KTEIPFDLGNK 64 53
12 477–486 TEIPFDLGNK 19 43
13 487–513 ITISTDAFEDTVTIPSPPTNVHASEIR 92 50
14 514–527 EAYVVLAWEEPSPR 65 55
15 530–538 APLTYSLEK 66 37
16 539–556 SVIGSGTWEAISSESPVR 86 57
17 560–567 FAVLDLEK 40 37
18 560–568 FAVLDLEKK 33 35
19 569–574 KSYVFR 32
20 577–596 AMNQYGLSDPSEPSEPIALR 69 58
21 597–612 GPPATLPPPAQVQAFR 79 42
22 613–638 DTQTSVSLTWDPVKDPELLGYYIYSR 33 18
23 639–657 KVGTSEWQTVNNKPIQGTR 27 23
24 640–657 VGTSEWQTVNNKPIQGTR 67 79
25 658–664 FTVPGLR 25 21
26 675–692 SVSEAGVGESSAATEPIR 96 63
27 714–724 NEMVIGWKPPK 38 26
28 731–757 ILGYFLDQHDSEELDWHAVNQQPIPTR 12
29 761–773 VSDLHEGHFYEFR 29
30 796–809 EWTMPQPGPPYDVR 43 26
31 863–870 VSDLQPGK 42 15
32 935–944 DYKGPLDPQR 55 23
33 956–993 VILKEPGLEDLGTYSVIVTDADEDISASHTLTEEELEK 25
34 960–993 EPGLEDLGTYSVIVTDADEDISASHTLTEEELEK 17
35 1008–1019 LISGWNIDILER 64 45
36 1024–1030 LWLEVEK 14 20
37 1031–1044 LSPAAELHLIFNNK 52 55
38 1045–1052 EIFSSPNR 25 20
39 1045–1053 EIFSSPNRK 26 28
40 1053–1058 KINFDR 26 22
41 1061–1075 GLVEVIIQNLSEEDK 52
42 1061–1086 GLVEVIIQNLSEEDKGSYTAQLQDGK 33 21
43 1089–1102 NQITLTLVDDDFDK 72 96
44 1089–1105 NQITLTLVDDDFDKLLR 60 23
45 1118–1129 QGPYFERPLQWK 16 14
46 1151–1157 FQWFFQR 22 23
47 1189–1218 AMVSDDRGEDDTILDLTGDALDAIFTELGR 88 32
48 1219–1228 IGALSATPLK 62 57
49 1229–1237 IQGTEEGIR 46 56
50 1244–1251 YYNVEYMK 40 30
51 1252–1257 TTWFHK 16
52 1269–1284 TGTTLDEIWLHILDPK 19 21
53 1291–1299 YTLEIAAGK 37 35
54 1303–1322 QLSTDLSGQAFEDAMAEHQR 40 38
55 1325–1331 TLAIIEK 17 24
Ion scores (Mascot MS/MS ion scores) are shown for each peptide identiﬁed in each band. The entire length of MYOM3 is 1437 aa. The obtained peptide coverage of the
MYOM3 suggests that both fragments have similar C-terminal end but different N-terminus. Minimum molecular weights of the fragments based on the positions of
the most N-terminal and C-terminal identiﬁed peptides are equal to 121 kDa for the upper fragment (1077 aa) and 96 kDa (855 aa) for the lower. Thus estimated MW
of the fragments ﬁt well with the positions of the fragments on the SDS-PAGE (130 and 100 kDa respectively).
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and 5 times lower than in young DMD patients. Of note, in two
outlier patients of 16 and 20 years old the levels of the MYOM3
fragments and CK were lower than themaximal values in the re-
spective healthy controls. The decrease of these proteins with
patient’s age can be explained by the severe loss of total muscle
mass due to the advanced stage of the disease.
Importantly, even if both proteins were able to discriminate
DMDpatients and healthy controls, therewere less inter-individ-
ual variations in MYOM3 fragment levels compared to CK levels.
While the CK levels in the young patients varied from 9000 to 60
000 IU/L (mean 27 130 IU/L ± 13 130), the values for MYOM3 frag-
ments remained between 11 a.u. and 24 a.u. (mean 19 a.u. ± 3).
The low correlation observed between the levels of serum CK
and MYOM3 fragments in the group of young patients (R2 = 0.28)
indicates that different physiological mechanisms may account
for the secretion/stability of these proteins at this age (Fig. 2C).
Conversely, these two biomarkers were well correlated in older
patients (Fig. 2D).
MYOM3 fragments are speciﬁcally present in sera
from animal models of DMD
The levels of MYOM3 fragments were quantiﬁed in two animal
models of DMD: golden Retriever muscular dystrophy (GRMD)
which has a severe phenotype similar to DMD patients (30) and
dystrophin-deﬁcient mdx mice. Western blot analysis of GRMD
and mdx sera revealed the presence of two bands migrating at
the same positions as human MYOM3 fragments (Fig. 3A and B).
Importantly, the abundance of these fragments was 100 times
higher than in the healthy control dogs. Whereas the level of the
MYOM3 fragments in human DMD samples decreased with age,
expression of these fragments was very similar in the serum of
2 and 18 months old ambulant GRMD. We hypothesize that the
high MYOM3 levels in elder GRMD can be due to the ambulant
state of the dogs. Age-independent expression of theMYOM3 frag-
ments could be an advantage for utilization of this biomarker in
gene therapy studies conducted in dogs.
MYOM3 fragments are elevated in sera of LGMD2D
patients and mouse models of LGMDs
The presence of the MYOM3 fragments was also analysed in
serum samples of three patients with α-sarcoglycanopathy
(LGMD2D). Fragments of the same length (100 and 130 kDa) were
detected at elevated levels in all these patients. Overall, the level
of these fragments in LGMD2D patients was lower compared to
their intensity in young DMD patients (Fig. 4, upper panel).
The following mouse models of limb-girdle muscular dystro-
phies were included in this study: KO-Calpain 3 (models for
LGMD2A) (31), KO-Dysferlin (models for LGMD2B) (32), KO-Sgcg
(models for LGMD2C) (33) and KO-Sgca (models for LGMD2D)
(34). These mouse models are congenic strains on the genetic
background of the C57BL/6J mouse, which was included in the
study as their wild-type (WT) control. Taking into consideration
the muscle impairment and time of disease onset, these mouse
models can be classiﬁed in terms of decreasing order of severity:
Figure 2. Expression levels of serumMYOM3 fragments (A) and CK (B) in sera from the entire US cohort including 39 young and 17 older DMD patients as well as 29 young
and 18 older healthy controls. To measure levels of the MYOM3 fragments, 50 μg of serum proteins were analysed byWestern blot, then band intensities were quantiﬁed
and expressed in arbitrary units (a.u). The CK enzyme activity in serum is expressed in international units per litre (IU/L). (C) Linear regression analysis between serum
levels of the MYOM3 fragments and CK for young patients. (D) Linear regression analysis between serum levels of the MYOM3 fragments and CK for older DMD patients.
The linearity of the response by Western blot for MYOM3 is demonstrated in Supplementary material, Figure S2.
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KO-Sgca, KO-Sgcg, KO-dysf and KO-Capn3. Serum from these
mouse models was collected at 1 and 6 months of age, corre-
sponding to the early and advanced stages of the dystrophies,
and the levels of the MYOM3 fragments were compared byWest-
ern blot. The highest levels of serumMYOM3 fragments were ob-
served in the three mouse models with perturbations in the
DAPC (Fig. 4, lower panel). In KO-Dysf mice, these fragments
were barely detectable at 1 month of age and then increased at
6 months, reﬂecting the aggravation of the disease at this age.
MYOM3 fragments were hardly detectable in KO-Capn3 mice at
any age.
Inmdxmice, the MYOM3 fragments are expressed early,
demonstrate less inter-individual variability and are less
sensitive to physical exercise compared to CK
In order to identify the earliest time point when the serum
MYOM3 fragments are detectable, we investigated sera from
mdx mice of different ages (from birth to 1-year-old). The
MYOM3 fragments were detected in mdx mice at birth, with a
small decrease in their levels at 1 week of age and followed by a
rise in abundance at 3 weeks (Fig. 5A). Importantly, the levels of
these fragments in the age-matched controlmicewas lower at all
ages tested (Fig. 5B). The kinetics of the MYOM3 fragment abun-
dance in the serum of mdxmice correlates with the timing of an
acute phase of muscle necrosis generally occurring at 3–4 weeks
of age, followed by an apparent stabilization of the muscle
phenotype (35). The kinetics of serum CK levels in mdx mice
were different from that of the MYOM3 fragments during the
ﬁrst weeks of age. Consistent with previous studies (36,37)
serum CK was elevated in newborn mice, but then became un-
detectable during the 1st and 2nd week of age (except for 1
mouse), rising again at 3 and 12 weeks followed by a stabilization
(Fig. 5C). In healthy mice, serum CK was also slightly elevated in
newborns and 12- and24-week-old animals (Fig. 5D). Importantly,
less variation was observed in the levels of MYOM3 fragments
in mice of the same age compared to the CK (maximum fold
change two for MYOM3 versus 110 for CK). The difference in
age-dependent expression patterns between serum CK and
MYOM3 fragments in mdx mice is probably related to different
mechanisms of bioprocessing of these proteins, especially during
the early phases of disease.
To assess the impact of physical exercise on the serum levels
of the MYOM3 fragments and CK, WT and mdx mice were sub-
jected to downhill running for 30 min. This exercise regimen is
often used to increase muscle injury and worsen themdx pheno-
type (38,39). Sera were collected 7 days before and 3, 24 and 48 h
after exercise. Importantly, while in mdx mice CK concentration
peaked at 3 h post-exercise (up to 10-fold increase) followed by
a substantial decrease (Fig. 6C), physical exercise had relatively
little impact on the serum levels of the MYOM3 fragments (less
than 2-fold increase 48 h post-exercise) (Fig. 6A). Interestingly,
in healthy mice, there was a slight increase in the levels of the
MYOM3 fragments 24 and 48 h after exercise, even though the
maximum level of the fragments in healthy mice was 50-fold
less than in mdx mice (Fig. 6B). Serum CK levels were variable in
Figure 3.MYOM3 fragments are speciﬁcally present in sera from animalmodels of DMD. (A)Western Blot analysis of serum fromGRMDandhealthy dogs. GRMD# 1–4: two
months old; # 5–6: 18months old. Healthy # 1–4: twomonths old; # 5–6: 18months old dogs. DMD: control serum fromDMDpatient. (B)Western Blot analysis of serum from
6 months old mdx and WT mice. WT: C57/BL10 strain.
Figure 4. Upper panel: Western blot analysis of the MYOM3 fragments in serum from 3 LGMD2D patients (#1 is 35, #2 is 23 and #3 is 24 years old). Serum from two DMD
patients (group G1) and three healthy individuals (group G4) were used as controls. Lower panel: Western blot analysis of the MYOM3 fragments in serum from mouse
models of differentmuscular dystrophies at 1 and 6months of age.WT: C57BL/6J mouse;mdx (model for DMD); KO-Sgcg:model for LGMD2C; KO-Sgca: model for LGMD2D;
KO-Dysf: model for LGMD2B; KO-Capn3: model for LGMD2A.
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healthy mice without noticeable correlation with physical exer-
cise (Fig. 6D). Given that MYOM3 is predominantly expressed in
slow and intermediate speed (type I and IIa) skeletal ﬁbres (29)
which are less affected in DMD relative to fast myoﬁbres (40), it
is possible that the difference in the kinetics of these biomarkers
is partially due to the differential sensitivity of thesemuscle ﬁbre
types to exercise-induced damage.
MYOM3 fragments enable monitoring of pharmaco-
and gene-therapy treatment efﬁcacy
The presence of the MYOM3 fragments in serum of DMD and
LGMD2D patients and their respective mouse models prompted
us to evaluate the utility of these biomarkers for monitoring the
response to experimental therapies in mdx and KO-Sgca mice.
Restoration of dystrophin expression in mdx mouse muscles
was achieved by a single administration of an arginine-rich cell-
penetrating peptide (CPP) conjugated to a phosphorodiamidate
morpholino oligonucleotide (PMO) that efﬁciently induces skip-
ping of exon 23 and restores dystrophin protein expression and
muscle function (41,42). In order to evaluate the impact of the
restoration of dystrophin expression on the serum levels of
MYOM3 fragments and CK, quadriceps femoris muscles and
blood samples from treated mdx were collected 2, 4 and 8
weeks post-injection. Quadriceps and blood samples from non-
treated mdx and WT control 12-week-old mice were taken as
controls. In accordance with the previously published data
(41–43), the restoration of the dystrophin expression and per-
centage of exon skipping in quadriceps were between 10 and
45% 2 weeks after injections, followed by a decrease at later
time points (Fig. 7A and B). In a good agreement with the restor-
ation of dystrophin levels, two weeks after injection the levels of
the MYOM3 fragments in treated mdx mice substantially de-
creased (without reaching the level in the control mice) and
then gradually increased over time (Fig. 7C). In contrast to the
MYOM3 fragments, CK levels did not reﬂect restoration of dys-
trophin expression. Thus, 2 weeks after injection the level of
serumCKwas lower in treatedmdxmice compared toWT control
mice (Fig. 7D), while dystrophin expression did not exceed 50% at
that time. Moreover, 8 weeks after the treatment, when the
estimated level of dystrophin-positive ﬁbres was around 10%,
CK levels were higher in treated than in non-treated mdx mice.
Different behaviour of the MYOM3 fragments and CK after par-
tial restoration of dystrophin expressionmay reﬂect the capacity
of these biomarkers to differentially reveal intracellular process
such as microparticle turnover (44) or increased myoﬁbrillar
protein catabolism (45,46).
To restore α-sarcoglycan expression in KO-Sgcamice, we used
recombinant adeno-associated virus rAAV2/8 vector. Control
C57BL/6J mice received an intravenous injection of PBS and
four groups of KO-Sgca mice received intravenous injections of
either PBS or low (1e11 vg), medium (5e11 vg) or high (1e12 vg)
Figure 5. Levels of the MYOM3 fragments (A, B) and CK-M (C, D) in serum from healthy (B, D) andmdx (A, C) mice at different ages as estimated byWestern blot analysis.
Intensity of the bands (in arbitrary units, a.u.) on different gels was normalized by the respective bands of the positive control (50 μg of serumproteins from the samemdx
mouse present on each gel). Fifty micrograms of serum proteins were used for the analysis. Age 0 corresponds to newbornmice. Estimation of the CK-M level byWestern
blot analysis correlated well with the CK activity (Supplementary material, Fig. S3).
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doses of rAAV2/8 coding for hSGCA. Mice were monitored for
3 months after the treatment. The following assays were com-
pared in order to deﬁne the most appropriate for the follow-up
of the treatment: histological analysis of muscle biopsies (HPS
staining and restoration of the sarcoglycan complex); total phys-
ical force 3 months after the treatment (1 week before animal
sacriﬁce); biweekly analysis of serum CK and MYOM3 fragments
levels.
Histological analysis of the gastrocnemius muscles demon-
strated restoration of the complex in 5–30% (mean 15.6 ± 8.4), 60–
100% (mean 79.2 ± 16.7) and 84–100% (mean 94.6 ± 8.8) of ﬁbres
after low, medium and high rAAV dose treatments, respectively
(Fig. 8A and B). Importantly, by assessing the expression level of
α-sarcoglycan (determined by immunostaining) the KO-Sgca, low,
medium andWTmice could be clearly distinguished. However, no
statistically signiﬁcant differencewas found betweenmediumand
high rAAVdoses by thismethod. Importantly, this analysis is high-
ly laborious, and the size of the biopsiesmakes it unsuitable for the
follow-up of the therapeutic effect in small animals.
Similar to histological analysis, the conventional whole body
tension (WBT) method is an end-point assay because mice be-
come accustomed to the protocol (47). The WBT method was
only able to discriminate two clusters of animals: (1) KO-Sgca
mice injected with PBS or low dose of rAAV and (2) control
C57BL/6J mice and KO-Sgca mice injected with medium or high
doses of rAAV (Fig. 8C).
A threshold 3000 IU/L of CK clearly separates KO-Sgca mice
injected with PBS from all other experimental groups (Fig. 8D).
Nevertheless, when applying the Student’s test (P-value
threshold < 0.01), differences only between few time points/
injection doses appeared as statistically signiﬁcant (Fig. 8F).
Changing of the P-value threshold to <0.05 permits to distinguish
more experimental groups of mice (Fig. 8F). Lower CK levels in all
groups of mice at day 90 (one week after the total force measure-
ments) (Fig. 8D) could be explained by the fact that an increase of
CK levels after physical exertion is followed by a substantial
decrease persisting for 2 weeks (48).
Inter-individual variations of theMYOM3 fragment levels were
lowercompared to serumCK in the caseof all experimental groups
(Fig. 8D and E). In accordance with a previous study showing pro-
gressive development ofmuscular dystrophy in KO-Sgcamice (34)
the levels of the MYOM3 fragments in the control mice injected
with PBS increased gradually with age (Fig. 8E). Even the lowest
dose of rAAV (1e11 vg) stabilized the MYOM3 fragment levels,
while medium and high doses reduced MYOM3 fragment levels
5-fold and 8-fold, respectively. Due to the low inter-individual
variability,measurement of theMYOM3 fragments enablednearly
all groups ofmice to be distinguishedwith either of the thresholds
(P < 0.01 or 0.05) at the majority of time points (Fig. 8E and F).
Furthermore, MYOM3 fragment abundance was better correlated
(R2 = 0.71) with muscle force as measured by the escape test com-
pared with CK (R2 = 0.59) (Supplementary material, Fig. S1).
Figure 6. Levels of the MYOM3 fragments (A, B) and CK-M (C, D) in serum from healthy (B, D) and mdx (A, C) mice at different time after physical exercise estimated by
Western blot analysis. Band intensity on different gels was normalized by the respective bands of the positive control (50 μg of serum proteins from the samemdxmouse
present on each gel). Fifty micrograms of mouse serum were used for the analysis.
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Discussion
In this study, the protein composition of serum samples from
DMD patients and their age-matched healthy controls were com-
pared using a label-free proteome proﬁling strategy. Using this
approach, 37 proteins were identiﬁed as differentially expressed
between young DMD patients and their age-matched controls.
Herewe discuss the utility of these proteins as potential diagnos-
tic or therapeutic biomarkers for muscular dystrophies.
Presence of CK and other cytosolic proteins in the serum
of DMD patients
Despite a large number of proteins with altered levels reported in
the serum of muscular dystrophy patients (49), CK is currently
the most widely used diagnostic tool in the early stages of DMD
and LGMD diagnosis (25,50). CK is predominantly a cytosolic pro-
tein: only a small amount of cytosolic CK (5–10%, depending on
muscle ﬁbre type) is speciﬁcally bound to the myoﬁbrillar M-
band, whereas the soluble major fraction can be extracted by
buffers of physiological ionic strength (51–53). The widespread
utilization of this biomarker can be explained by the low cost of
its assessment, the high sensitivity of existing CK assays, the ex-
cellent negative predictive value and also by a textbook explan-
ation for the elevation of this protein in the blood of DMD
patients: leakage due to the increased fragility of the sarcolemma
in myoﬁbres in the absence of dystrophin. While the membrane
of normalmuscle ﬁbres can be quickly repaired (54), perturbation
of the DAPC could increase repair time thus leading to the leak-
age of cytosolic proteins into the bloodstream. Increased levels
of glycolytic enzymes (pyruvate kinase, L-lactate dehydrogenase,
β-enolase, fructose-bisphosphate aldolase A, glycogen phos-
phorylase, glucose-6-phosphate isomerase, triosephosphate
isomerase) which are also considered to be soluble constituents
of the cell (55,56) in the bloodstreamof patients support this leak-
age hypothesis. It is highly probable that most of the cytosolic
proteins with increased levels in DMD patient serum could be
used as biomarkers in DMD equally to CK. Thus, excellent correl-
ation between the levels of CK and pyruvate kinase was found in
sera fromDMD and Becker patients (23). Nevertheless, we cannot
exclude dysregulation of vesicle trafﬁcking due to lack of dys-
trophin as a possible source of cytosolic/cytoskeletal proteins in
DMD patient serum (44).
Secreted proteins
Of the 24 proteins enriched inDMDpatient sera only haptoglobin,
which is known to be elevated during inﬂammatory processes
(57), is known to be secreted. Intriguingly, all 13 proteins with de-
creased levels in DMD patient sera were either secreted or mem-
brane components. The secreted proteins exhibited lower fold
changes between DMD and healthy controls compared to cyto-
solic or structural proteins (maximum 5-fold versus 250-fold, re-
spectively) and higher P-values. However, these proteins could be
useful in DMD prognosis if they appear to be correlated with
clinical outcome, natural history or therapeutic response, and
further studies are needed to deﬁne their roles in disease devel-
opment. Interpreting the biological meaning of these secreted
factors by using the Ingenuity software (http://www.ingenuity.
com) indicated the involvement of lipid and carbohydrate
metabolism in the disease. In accordance with these ﬁndings,
recent publications described perturbation in lipid (58) and
glycogen metabolism (59) in human DMD myoblasts and mdx
mice respectively.
Cytoskeletal proteins
Of the 37 proteins with altered levels at the early stage of the dis-
ease, seven were cytoskeletal (MYOM2, MYOM3, Myosin-7, Fila-
min-C, Titin, Vinculin and Tropomyosin β chain). All these
proteinswere upregulated in sera fromDMDpatients. Importantly,
increased levels of fragments of MYOM3, Titin and Filamin-C
were recently demonstrated in sera of a small cohort of DMD pa-
tients (49). The presence of the structural myoﬁbrillar proteins in
the bloodmay be due to the accelerated remodelling ofmuscle ﬁ-
bres in DMD patients accompanied by an increased secretion of
protein fragments, or by the catabolic process of the damaged ﬁ-
bres and muscle necrosis. Independently of the mechanisms
underlying the appearance of these proteins in the bloodstream,
we sought to evaluate whether the levels of myoﬁbrillar proteins
in serum could be used for treatment monitoring in DMD,
LGMD2D and potentially in other forms of muscular dystrophy.
Based on the high fold change and low P-value between DMD
Figure 7. Effect of antisense oligonucleotide-mediated exon-skipping therapy in
mdx mice on the serum levels of the MYOM3 fragments and CK-M. Twelve 12-
week-old male mdx mice were treated with a single 12.5 mg/kg intravenous
dose of Pip6a-PMO. Two, 4 and 8 weeks after injections the animals were
sacriﬁced by groups of four mice and quadriceps and blood samples were taken
for analysis. Dystrophin restoration in quadriceps muscles was monitored by
Western blot analysis (A) and the efﬁciency of exon skipping by qPCR analysis
(B) (See Materials and Methods section for the details). Levels of the MYOM3
fragments (C) and CK-M (D) were measured by Western blot analysis, and then
band intensities were quantiﬁed and expressed in arbitrary units (a.u).
Additional data conﬁrming the robustness of dystrophin quantiﬁcation are
presented in Supplementary material, Figure S4. (E): Raw P-values (Student’s
t-test) for the comparison of MYOM3 and CK levels between different groups of
mice at different time points. The values below the threshold 0.01 are in yellow,
and below 0.05 are in pink.
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and healthy controls, and also on the availability of antibodies,
MYOM3 protein was chosen for this further analysis.
MYOM3 fragments as biomarkers for therapeutic
outcome measurements
Myomesins are the principal components of the cytoskeletal
structure called the M-band that cross-links ﬁlamin-C and
titin ﬁlaments in the middle of the sarcomere (60). There are
three closely related structural forms of this protein:myomesin
(MYOM1) and M-protein (MYOM2) and myomesin 3 (MYOM3).
According to amino acid alignment, the identity level between
MYOM3 and MYOM1 or MYOM2 is about 40%, and all three pro-
teins share the same domain arrangement (29). It was sug-
gested, that similarly to titin, myomesin is a molecular spring
whose elasticity guards the stability of the sarcomere (61,62).
Expression of MYOM3 was found mainly in intermediate
speed ﬁbres (type IIa) of skeletal muscle, while fast ﬁbres ex-
press more MYOM2 and MYOM1 is expressed in all muscle
ﬁbres (29).
Presence of the two fragments of 100 and 130 kDa in the sera
of DMD patients as well as LGMD2D patients and in different
animal models of DMD (mdx mouse, GRMD dog) and other
forms of muscular dystrophy indicates a conserved mechanism
of MYOM3 proteolysis and release across species and diseases.
This mechanism is possibly linked to the activation of calcium-
dependent proteolysis pathways such as those involving the ubi-
quitous calpains (63). Importantly, there was a clear difference in
the time-course of cytosolic CK and structural MYOM3 proteins
appearance in the bloodstream of mdx mice after physical exer-
cises. In accordance with published data, the CK levels varied
as much as 20-fold with a peak at 3 h after exercise (48), while
the amounts of the MYOM3 fragments increased only by 2-fold,
peaking at 2 days after exercise. Moreover, serum CKwas present
as a complete protein, while MYOM3 was present as two frag-
ments. To explain the different behaviour of these cytosolic
and structural proteins, we suggest that the minor injuries that
are reparable by the membrane reparation machinery (64) are
sufﬁcient to allow the escape of cytosolic proteins into the blood-
stream. More severe damage can lead to the failure of membrane
repair and trigger myoﬁbre necrosis (65) followed by proteolysis
and solubilization of structural myoﬁbrillar proteins. Thus, the
progressive rounds of myoﬁbre necrosis followed by rounds of
muscle ﬁbre regeneration characteristic of DMD muscles can
Figure 8. Comparison of different assays for the follow-up of the gene therapy treatment in KO-Sgca mice. (A) Histological analyses (upper panel: HPS stain; lower panel:
immunodetection of α-sarcoglycan) of gastrocnemius muscles after treatment with increasing doses of rAAV coding for huSgca (1e11, 5e11 and 1e12 vg). (B) Quantitative
analysis of α-sarcoglycan positive ﬁbres after the treatments. (C) Restoration of muscular strength (escape test) 83 days after the treatment. (D) Serum CK and (E) MYOM3
fragments levels at different time after the treatment (mean ± SEM). (F) Raw P-values (Student’s t-test) for the comparison of MYOM3 and CK levels between different
groups of mice at different time points. The values below the threshold 0.01 are in pink, and below 0.05 are in yellow. PBS, 1e11, 5e11 and 1e12: KO-Sgca mice injected
with PBS or the respective dose of the vector. WT: C57BL/6J control mice injected with PBS. Levels of the MYOM3 fragments and CK-M were estimated biweekly by
Western blot analysis.
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lead to the appearance of both, cytosolic proteins and structural
myoﬁbrillar protein fragments in the bloodstream, while low
level membrane damage results in the release of cytosolic pro-
teins only. Low correlation between the levels of theMYOM3 frag-
ments and CK in young patients favours this hypothesis.
Nevertheless, we cannot exclude that the abnormal presence of
cytoskeletal proteins in sera of DMD patients is due to dysregula-
tion of vesicle trafﬁcking in the absence of dystrophin (44). The
differences in the biogenesis of these biomarkers suggests that
structural proteins can be a complementary to the cytosolic pro-
teins such as CK with the former reﬂecting more severe muscle
damage while being less sensitive to occasional myoﬁbre leak-
age. However, the behaviour of serum biomarkers cannot be sim-
ply predicted on the basis of cytosolic or structural classiﬁcation.
Thus, products of proteolysis of another structural protein titin
can be found in serum (our data not shown) and urine of mdx
mice as early as 3 h after physical exercise (22). The different be-
haviour of titin and MYOM3 can be due to the particular role of
titin as a sensor of mechanical load (66).
Comparison of MYOM3 fragments with three other assays
(biopsy, restoration of physical force and CK) in models of two
different muscular dystrophies, mdx (dystrophin deﬁcient) and
KO-Sgca (α-sarcoglycan deﬁcient), demonstrated the superiority
of MYOM3 fragments for the follow-up of gene therapy treat-
ments relative to other assays. The advantages of the MYOM3
fragments compared to CK are their lower inter-individual vari-
ability between the patients of the same age, better correlation
with the reconstitution of the dystrophin-associated protein
complex and muscle force restoration. The critical advantages
of the MYOM3 fragments compared to the histological analysis
of biopsies are that they are less invasive and provide informa-
tion concerning body-wide muscle integrity. MYOM3 was the
most efﬁcient biomarker for distinguishing the ﬁve groups of
KO-Sgca mice treated with different doses of rAAV vector. Im-
portantly, for none of the recently proposed biomarkers based
on quantiﬁcation of serum miRNA (19,20,67) or proteins (28,68),
a therapy-dose-dependent return to normal values has been
shown so far. This is a crucial advantage of MYOM3 compared
to other proposed proteins or miRNAs for which this remains to
be shown. Even if miRNAs could potentially provide a similar de-
gree of qualitative or quantitative information concerning ther-
apy response, this method remains more laborious and costly.
For the moment however, primary data are still missing.
Taken together, our data demonstrate thatMYOM3 fragments
are promising candidate biomarkers for monitoring therapeutic
outcomes in DMD and other muscular dystrophy patients.
Materials and Methods
Human sample collection
Thehuman studieswere conducted according to the principles of
the declaration of Helsinki “Ethical Principles for Medical Re-
search Involving Human Subjects”. Serum samples from a cohort
of 39 young (3–10 years old) and 17 older (12–20 years old) DMD
patients as well as 29 young (3–10 years old) and 18 older (12–20
years old) healthy individuals were collected at the Cincinnati
Children’s Hospital Medical Center USA (US cohort) as part of
ADNA (Avancées Diagnostiques pour de Nouvelles Approches
thérapeutiques) project (http://www.institut-merieux.com/
projetssante_adna.php). All young patients were ambulant,
while all older patients were wheelchair bound. None of the pa-
tients was treated with corticosteroids, and all patients with a
CRP level higher than 1 mg/dl were excluded from the study.
Age, genetic alterations, CK and MYOM3 levels of DMD patients
in the cohort are shown in Supplementary Material, Table S1.
The study protocol and Informed Consent was approved by the
Institutional Review Board (IRB) at Cincinnati Children’s Hospital
Medical Center. Informed Consentwas obtained fromall subjects
prior to the study. The conduct of the study conforms to all
applicable human subjects research regulations. We could pro-
vide documentation upon request. Serum samples from three
LGMD2D patients were collected at the Neuromuscular Research
Center (University Hospital of Tampere, Finland) during standard
day-care consultation. All three patients were homozygous for
299CGC > TGC (R77C) mutation in the alpha-sarcoglycan gene.
Patients of 35 and 24 years old were non-ambulant, while 23
years old patient was ambulant at the time of the blood draw.
After collection, samples were centrifuged twice immediately
(10 000 × g, 10 min) and serum was stored at −80°C.
Protein quantiﬁcation and measurements of CK activity
Protein concentration was determined using the Bio-Rad Protein
Assay Dye Reagent (Bio-Rad) according to the manufacturer’s in-
structions with bovine serum albumin as a standard. Measure-
ments of total CK activity were performed using the Vitros
DT60 II Chemistry System according to the manufacturer’s
instructions (Ortho-Clinical Diagnostics).
Serum depletion
Depletion of the 12 most abundant serum proteins (alpha 1-acid
glycoprotein, alpha 1-antitrypsin, alpha 2-macroglobulin, albu-
min, apolipoprotein A-I, apolipoprotein A-II, ﬁbrinogen, hapto-
globin, IgA, IgG, IgM and transferrin) was performed with the
Proteome purify 12 Human Serum Protein Immunodepletion kit
(R&D Systems) according to themanufacturer’s instructionswith
some modiﬁcations. Brieﬂy, 1 ml of immunodepletion resin was
mixed with 10 μl of pooled serum diluted with PBS to a ﬁnal vol-
ume of 500 μl and incubated for 1 h at room temperature (RT). De-
pleted serum was collected after centrifugation (1000 × g, 2 min)
in Spin-X Filter Units and proteins were 5-fold concentrated
using Amicon Ultra-2 Centrifugal Filter Units (cut-off 3 kDa;
Millipore) following the manufacturer’s instructions.
MYOM3 fragments puriﬁcation
MYOM3 fragments were puriﬁed from 500 μl of DMD patient
serum by immunoprecipitation with anti-MYOM3 antibodies
(Proteintech: 17692-1-AP) immobilized on A/G sepharose. After
ﬁve washing with PBS supplemented with 0.5% of Triton X-100
immunoprecipitated proteins were separated by SDS-PAGE and
Coomassie stained. Two bands migrating at the same positions
as on the Western blot analysis were taken for the mass spec-
trometry analysis using LTQ Velos Orbitrap mass spectrometer
(Thermo Fisher Scientiﬁc).
Mass spectrometry
Formass spectrometryanalysis, 10 μg of depleted serumproteins
were solubilized in a total of 123 μl of the reaction mixture con-
taining 4 M urea, 1.5 M thiourea and 50 m tris–HCl pH 8.3. Pro-
teins were reduced with 10 m dithiothreitol for 30 min and
then alkylated with 55 m iodoacetamide for 20 min. Alkylated
proteins were ﬁrst digested with 500 ng of endopeptidase lys-C
(Wako) for 3 h at RT. Then, the mixture was adjusted to 235 μl
with MilliQ-water and treated with 500 ng of trypsin (Sequence
Grade Trypsin, Promega) for 16 h at RT. Enzymatic activity was
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stopped by addition of formic acid to 3% ﬁnal concentration and
samples were stored at −20°C until use. The peptide mixture was
desalted using ZipTipμ-C18 Pipette Tip (Millipore) and separated
with an Easy nano-LC Proxeon system (Thermo Fisher Scientiﬁc)
equipped with a reversed phase C18 column (Easy-Column Prox-
eon C18, L 10 cm, ID 75 μm). Eluates were monitored by a LTQ
Velos Orbitrap mass spectrometer (Thermo Fisher Scientiﬁc)
and tandemMS (MS/MS) datawere processedwith Proteome Dis-
coverer 1.4 software (Thermo Fisher scientiﬁc) coupled to an in
house Mascot search server (Matrix Science, 2.3.2 213 version)
using SwissProt database as described previously (22). The rela-
tive abundance of each protein identiﬁed in serum from DMD
or healthy patients was estimated by label-free quantiﬁcation
using the Progenesis LC-MS software (Nonlinear Dynamics, 4.0
version).
Western blot
Protein samples were separated by SDS-PAGE electrophoresis
(4–12% gradient, NuPAGE Novex Bis-Tris Gel 1.0 mm, Life Tech-
nologies) and transferred onto Protran Premium membrane
(nitrocellulose, GE Healthcare). Fifty micrograms (1 μl of serum)
of human, mouse or dog serum protein were loaded per lane.
Antibodies against MYOM3 (1:1000, Proteintech: 17692-1-AP)
and the CK-M (1:500, Santa Cruz: sc-15161) were used as primary
antibodies followed by incubationwith the corresponding IRDye-
800CW-conjugated antibodies (1:10 000, LI-COR Biosciences) ac-
cording to themanufacturer’s instructions. Infraredﬂuorescence
of the secondary antibodieswas read on anOdyssey Imaging Sys-
tem (LI-COR Biosciences). Band intensities weremeasured by the
Odyssey application software (LI-COR Biosciences, Image Studio
Lite 4.0 Version). The following antibodies were not efﬁcient in
Western blot analysis of human serum: anti-Myomesin 3
sc-165061; anti-Myomesin 2: sc-30384; sc-30385; sc-50435; anti-
Myosin: ABIN502241; ABIN616957; sc-53089; sc-20641; sc-32732;
sc-53096.
Animal experimentations
Animal experimentations were conducted in accordance with
the European guidelines for the protection of vertebrate animals
used for experimental purposes (Directive 2010/63/EU of 22 Sep-
tember 2010) and for the mice treated with the oligonucleotide
Pip6a-PMO, in accordance to procedures authorized by the UK
home ofﬁce. Blood samples were collected from ambulant male
dogs (provided by the CEDS at Mézilles and Oniris at Nantes,
France) from the lateral saphenous vein and from mice by
retro-orbital bleeding or from the jugular vein. The following
mouse strains were used: C57BL/6 and C57/BL10 control strains
as well as mdx [model for DMD: (69)], and four knockout (KO)
strains named KO-Capn3 [model for LGMD2A: (70)], KO-Dysf
[model for LGMD2B: (32)], KO-Sgcg [model for LGMD2C: (33)] and
KO-Sgca [model for LGMD2D: (34)]. Blood samples were centri-
fuged twice (10 000 × g, 10 min, 4°C) and serum samples obtained
were stored at −80°C until use.
Physical exercise of mice
Mice were placed on a treadmill (Treadmill Exer 6M, Columbus
Instruments) to run at a downward inclination of 15° at speeds
of 8 m/min for 5 min, followed by 12 m/min for 25 min. Blood
samples were collected by retro-orbital bleeding and sera were
stored at −80°C.
Ageing in mice
Serum samples from 1-day up to 52-week-old mice (ﬁve healthy
controls or ﬁve mdx per age) were stored at −80°C. Newborn as
well as 12-, 24-, 36- and 52-week-old mice were euthanized
after collection. The samples for the 1-, 2-, 3- and 4-week time
points were collected from the same group of mice.
Antisense oligonucleotide-mediated exon-skipping
therapy of mdxmice
Twelve-week-oldmdxmicewere treated with a single 12.5 mg/kg
tail vein injection of an arginine-rich CPP conjugated to a
PMO, Pip6a-PMO (peptide RXRRBRRXRYQFLIRXRBRXRB coupled
through an amide linkage at the 3′ of the oligonucleotide
5′-GGCCAAACCTCGGCTTACCTGAAAT-3′), synthesized and pre-
pared in a sterile saline solution as described previously (42,67).
Two, 4 and 8 weeks post-injection animals were sacriﬁced by
groups of four mice and quadriceps and blood samples were
taken for analysis. The blood at 12 weeks was collected by
retro-orbital bleeding and at 14, 16 and 20 weeks through jugular
vein (end-point bleeds) and the serum levels of the MYOM3 frag-
ments and CK-M were monitored by Western blot analysis. Dys-
trophin restoration in quadriceps muscles was followed up by
Western blot analysis and the efﬁciency of exon skipping by
qPCR analysis.
To assess dystrophin protein restoration, quadriceps cryo-
sections were lysed in buffer (75 mmol/l Tris–HCl (pH 6.5),
10% sodium dodecyl sulphate, 5% 2-mercaptoethanol and pro-
tease inhibitors) prior to centrifuging at 13 000 rpm for 10 min.
After heating at 100°C for 3 min supernatant was fractionated
on a 3–8% Tris-Acetate gel. Proteins were transferred and
probed with a monoclonal anti-dystrophin (1:200, NCL-DYS1,
Novocastra) and anti-vinculin (loading control, 1:100 000,
hVIN-1, Sigma) antibodies. Secondary antibody IRDye-800CW
goat anti-mouse was used at a dilution of 1:20 000 (LiCOR).
Fluorescence was detected and quantiﬁed using the Odyssey
imaging system. There was no saturation of signal using this
methodology, thereby allowing for dystrophin protein quantiﬁ-
cation over awide linear dynamic range. Dystrophin expression
was quantitated using the dystrophin to vinculin ratio versus
C57BL10 wild-type dystrophin expression level standards on
each gel.
To investigate the duration of exon skipping after Pip6a-
PMO administration, RNA was extracted from quadriceps
cryo-sections using Trizol (Invitrogen). A total of 1 μg of RNA
was reverse transcribed using the High Capacity cDNA RT Kit
(Applied Biosystems, Warrington, UK) according to manufac-
turer’s instructions. qPCR analysis was performed using 25 ng
cDNA template and Taqman Gene Expression Master Mix
(Applied Biosystems, Warrington, UK) on a StepOne Plus
Thermocycler (Applied Biosystems, Warrington, UK). Levels of
dystrophin exon 23 skipping was determined by multiplex
qPCR of FAM-labelled primers spanning Exon 20-21 (Assay
Mm.PT.47.9564450, Integrated DNA Technologies, Leuven, Bel-
gium) and HEX-labelled primers spanning Exon 23-24 (Mm.
PT.47.7668824, Integrated DNATechnologies, Leuven, Belgium).
The percentage of dystrophin exon 23 transcript skipping was
determined by normalizing exon 23-24 ampliﬁcation levels to
exon 20-21 levels.
Gene therapy treatment of KO-Sgca mice
Recombinant adeno-associated virus 8 (rAAV2/8) vectorwas used
to restore α-sarcoglycan expression in KO-Sgca mice. The
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production of rAAV was performed by dual infection of Sf9 cells
with baculoviruses harbouring cDNA for Sgca under the desmin
promoter and regulated by miR-142-3p (71) and AAV rep2/cap8
genes (rAAV2/8). The puriﬁcation was performed on immuno-af-
ﬁnity AVB sepharose medium (GE Healthcare) according to (72).
Four groups of 5-week-old KO-Sgcamice (ﬁvemice per group, ex-
cept four mice for the highest vector dose) were injected either
with PBS or with increasing doses of rAAV [1e11, 5e11 and 1e12
viral genome (vg)]. Blood samples were collected biweekly for 3
months and levels of the MYOM3 fragments and CK were moni-
tored byWestern blot analysis and measurements of CK activity,
respectively. Muscle force was measured by the escape test 1
week before sacriﬁce. Restoration of the sarcoglycan complex
and muscle morphology was assessed by immunostaining and
histological analyses.
Evaluation of muscle force in mice
Mousemuscle forcewas evaluated by theWBTmethod or escape
test (73) with somemodiﬁcations. Mice attached to the tail with a
thread connected to a tension transducer were placed on a plat-
form facing the entrance of a 30 cm long tube. In response to
pinching of the tail, mice try to escape within the tube thus rais-
ing a short peak of force (forward pulling tension, FPT) that is re-
corded. Five FPTswere recorded for eachmouse. The bodyweight
of each mouse was measured and the WBT was obtained by div-
iding the average of the ﬁve FPTs with the body weight.
Statistical analysis
Statistical analyses were performed using the GraphPad Prism
version 6.04. Data are expressed as mean ± SD if not otherwise
speciﬁed. For comparisons between means, homogeneity of var-
iances was assessed by Fisher–Snedecor’s test and the Student’s
t-test (two-tailed) was applied. Pearson’s correlationwas used for
correlation studies and datawere analysedwith a 95% conﬁdence
interval and P < 0.05 was considered signiﬁcant.
Histology and Sgca immunostaining
Cryosections (8 mm thickness) were prepared from frozen right
and left gastrocnemius muscles. Transverse sections were pro-
cessed for haematoxylin phloxine saffron (HPS) histological
staining. Colorimetric immunodetection of Sgca was performed
as previously described (74).
After digitization of immunostained biopsies (Axioscan,
ZEISS) the total surface of the biopsies and the surface stained
for α-sarcoglycan were quantiﬁed using the ImageJ sofware (ver-
sion 1.47 g 64-bits, Rasband,W.S., ImageJ, U. S. National Institutes
of Health, Bethesda, Maryland, USA, http://imagej.nih.gov/ij/,
1997–2014) and a customized script (available on demand). The
percentage of Sgca positive ﬁbres for a given biopsy was calcu-
lated using the following equation: (number of Sgca positive pix-
els on the biopsy area/surface in μm² of the biopsy area) divided
by the same ratio obtained for healthy control (number of Sgca
positive pixels on the biopsy area/surface in μm² of the biopsy
of the control C57BL/6J mouse) and multiplied by 100.
Supplementary Material
Supplementary Material is available at HMG online.
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